Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Depreciation (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Accumulated Depreciation for 4 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 30.69% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, up 30.69% year-over-year, with the annual reading at $4.7 million for FY2025, 30.69% up from the prior year.
  • Accumulated Depreciation hit $4.7 million in Q4 2025 for Taysha Gene Therapies, up from $4.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $4.7 million in Q4 2025 to a low of $754000.0 in Q1 2022.
  • Historically, Accumulated Depreciation has averaged $2.9 million across 4 years, with a median of $3.1 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation: surged 161.67% in 2023 and later rose 12.03% in 2025.
  • Year by year, Accumulated Depreciation stood at $1.6 million in 2022, then surged by 81.43% to $3.0 million in 2023, then grew by 20.31% to $3.6 million in 2024, then skyrocketed by 30.69% to $4.7 million in 2025.
  • Business Quant data shows Accumulated Depreciation for TSHA at $4.7 million in Q4 2025, $4.4 million in Q3 2025, and $4.1 million in Q2 2025.